05.20.25 -- STREAM Edition: Optimization-By-Design — A Critical Factor In Viral Vector Scale Up

Explore the future of cell and gene therapy by joining our webinar. With over 450 unique products currently in clinical development and an estimated 50 approvals by 2030, staying informed on the evolving regulatory landscape is essential for industry stakeholders. Cell & Gene Live offers valuable insights, providing forward-looking perspectives on regulations that will shape the trajectory of cell and gene therapies. Don't miss the opportunity to gain critical knowledge. Watch now and learn more.

Learn how leveraging the expertise and capabilities of an experienced partner is a key factor in optimizing AAV processes using Design of Experiment (DoE), thereby reducing variability and risk.

Watch part 1 of a four-part series, "Four Common Types Of Cryogenic Studies For Advanced Therapies," to learn about controlled-rate freezing studies.

Accelerate your AAV production journey. Learn how rapid process development and expert support can streamline your path from vial to purified bulk, ensuring scalable and efficient manufacturing.

One of the continued challenges for scalable commercial manufacturing of cell therapies is closing and automating the entire manufacturing process. 

In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a developer of autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases.

Discover more about optimized storage, packing, labeling, and global distribution, seamlessly integrated for your supply chain. Simplify complexity and enhance the reliability of your supply chain.